Name: Vertigo: The Most Common Kind Is Cured in Minutes, Not With Pills
Creator: Realised
Published: 2026-06-01

Summary

The single most common cause of vertigo — benign paroxysmal positional vertigo (BPPV) — is a purely mechanical fault: tiny calcium-carbonate crystals (otoconia) have fallen loose into a semicircular canal, and a two-minute bedside repositioning manoeuvre (the Epley) physically returns them and resolves the spinning, often in one visit, with strong Cochrane/RCT support — yet the cure is drastically under-used (roughly one in nine primary-care BPPV patients gets it) while the default is a vestibular-suppressant drug that does not fix the crystal displacement, can prolong it, and sedates; the hon

Why Strong

Strong Evidence because the entry's load-bearing claims rest on gold-standard sources pointing the same way. The curative claim is a Cochrane systematic review of RCTs (the Epley manoeuvre is safe and effective for posterior-canal BPPV), reinforced by a second Cochrane review showing the repositioning geometry itself is the active ingredient. The recommendation against routine vestibular suppressants is a national specialty-society guideline. The red-flag exam (HINTS more sensitive than early MRI for stroke in acute vestibular syndrome) is a landmark prospective diagnostic-accuracy study. These are convergent, high-quality, and mostly conflict-clean.

NOT Foundational because the entry carries clinical judgement and a live both-ways tension (reposition-don't-medicate versus don't-miss-the-stroke), not a single undisputed axiom.

The internal split (read this, not just the headline):
• Epley manoeuvre resolves posterior-canal BPPV: Strong (Cochrane review of RCTs).
• The geometry is the active ingredient (add-ons add nothing): Strong (Cochrane review).
• Don't routinely use vestibular suppressants for BPPV: Strong (national guideline, explicit recommendation-against).
• HINTS out-performs early MRI for stroke — in expert hands: Strong for the exam, with a hard examiner-dependence caveat.
• The curative manoeuvre is under-delivered (~11% in primary care): Moderate (observational cohort).
• Betahistine benefit for vertigo generally: Emerging/low-grade — and not a BPPV cure at any tier.
• Suppressants prolong BPPV: mechanistic-plus-guideline-logic, not RCT-proven — held as delay-of-cure, not hard causation.

Practical takeaway

The framing to hold: the commonest true vertigo is a mechanical fault with a mechanical fix. If it is confirmed BPPV, the evidence-based first move is a repositioning manoeuvre, not a prescription — but confirming it, and clearing the dangerous mimic, comes first.

Step zero — is it actually vertigo, and is it safe?
• Is the room spinning, or are you about to faint? True rotatory vertigo points toward the vestibular system (and, if positional, toward BPPV). Lightheadedness/presyncope or general unsteadiness is a different work-up — see fatigue_cross_pillar_diagnostic and, for blood-pressure/cardiac causes, cardiovascular_health_management.
• Screen for the emergency FIRST. Sudden, severe, continuous vertigo with ANY of: new or severe headache, double vision, slurred speech, facial or limb weakness or numbness, inability to stand or walk unaided, or eyes that jerk in a changing or vertical direction — is a same-day emergency. Do not attempt a manoeuvre; get urgent assessment to exclude stroke.

If it looks like BPPV (brief spins triggered by head position changes — rolling over in bed, lying down, looking up):
• Get it confirmed, don't just assume. A clinician performs the Dix-Hallpike test; a positive result shows the characteristic brief latency then torsional, up-beating nystagmus. That confirmation matters because different canals (horizontal, anterior) need different manoeuvres, and atypical patterns need a proper look.
• The treatment is the Epley manoeuvre, not a drug. It is the evidence-based first-line move, frequently effective in a single session. Ask for it by name if you are handed a prescription instead.
• Don't accept a vestibular suppressant as "the treatment." Guideline advice is against routine use; they mask the symptom, can delay the cure, and sedate. A short course purely to tolerate acute nausea is a different, limited role — not a substitute for repositioning.
• Skip the "vertigo supplements." Ginkgo, vitamin blends and ear-health products have no mechanism to reposition a crystal.

On self-treatment (self-Epley): self-administered manoeuvres exist and can help once BPPV is diagnosed and the canal identified — but the sequence must be the one matched to your canal, and, critically, the stroke rule-out is not a step you can do at home. Treat a first episode, an atypical episode, or any episode with red-flag features as a clinician visit, not a YouTube exercise.

Know the honest ceiling. Repositioning is highly effective for posterior-canal BPPV, but BPPV recurs in a meaningful fraction of people over time, and repeat manoeuvres may be needed. Recurrent or persistent vertigo, or vertigo with hearing loss or ear fullness (suggesting Ménière's disease) or with a viral prodrome and days of continuous spinning (suggesting vestibular neuritis), warrants clinician assessment rather than another self-manoeuvre — and any ear-symptom overlap (ringing) routes to tinnitus_evidence_and_management.

Evidence detail

Why This Entry Exists

Vertigo is one of the most mishandled complaints in everyday medicine, and it is mishandled in two opposite directions at once. On one side, the commonest cause of true spinning vertigo is a mechanical problem with a proven, free, minutes-long fix that almost nobody receives — patients instead walk out with a bottle of a drug that treats the symptom and not the cause. On the other side, a small but critical fraction of "sudden vertigo" is not the inner ear at all but the brainstem or cerebellum — a posterior-circulation stroke wearing the mask of a benign spin. An entry that only shouts "stop taking pills, just reposition it" would be dangerous; an entry that only says "always see a doctor for dizziness" would bury the single most useful fact in the field. This entry has to hold both.

The core fact is genuinely liberating and genuinely under-taught: BPPV is displaced ear crystals, and the Epley manoeuvre uses gravity and head geometry to walk them back where they belong. Cochrane rates it safe and effective. No drug does this, because no drug moves a crystal. But the same specificity that makes the manoeuvre work is what makes the red flag non-negotiable — the manoeuvre and the "it's just your ears" reassurance apply ONLY to confirmed positional vertigo, and confidently self-diagnosing your way past a stroke is the failure mode that kills.

What bad advice this protects against, in all directions:
• "Take a vertigo pill and wait it out" → vestibular suppressants (meclizine, betahistine) treat the sensation, not the crystal displacement; national guideline advises AGAINST routine use, and they sedate, worsen balance, and raise fall risk in the elderly.
• "Vertigo supplements (ginkgo, ear-health blends) will fix it" → there is no mechanism by which a supplement repositions an otolith; this is demand-riding with no BPPV rationale at all.
• "Betahistine is the proven vertigo drug" → the best-quality (blinded, placebo-controlled) evidence for betahistine is weak and low-grade, and it is not a BPPV cure regardless; the impressive-looking evidence is the industry-funded, uncontrolled kind.
• "Any dizziness means reposition your crystals" → true spinning vertigo is a different problem from lightheadedness/presyncope ("about to faint") or unsteadiness; the crystal story applies only to genuine positional spinning.
• "Sudden severe vertigo just needs bed rest" → sudden, severe, continuous vertigo WITH any neurological sign can be a posterior-circulation stroke; early MRI can miss it in the first 24–48h; this is a same-day emergency.
• "I'll just do the Epley off a YouTube video and skip the doctor" → the manoeuvre is for CONFIRMED posterior-canal BPPV (Dix-Hallpike positive); other canals need different manoeuvres, and self-treatment that skips the stroke rule-out inverts the whole point.
• "Repositioning doesn't really work, it's a gimmick" → the reverse over-correction; the Cochrane evidence for the Epley manoeuvre is Strong, and dismissing it leaves people on ineffective drugs.

This entry owns the "it's mechanical, reposition it" verdict for BPPV and the peripheral-versus-central red-flag boundary for acute vertigo. It defers actual stroke/cardiovascular management to cardiovascular_health_management, the ear-symptom neighbour (tinnitus) to tinnitus_evidence_and_management, and the broader "why am I dizzy/exhausted" differential work-up to fatigue_cross_pillar_diagnostic. It states those boundaries and routes there rather than re-arguing them.

Evidence

Organised by claim, with the tier signal inline. The curative-manoeuvre evidence and the guideline recommendation-against-drugs are the firmest parts; the red-flag exam and the practice-gap data are the load-bearing safety and context.

The cure: repositioning works, and it is the active ingredient (Strong).

1. The Epley (canalith-repositioning) manoeuvre is a safe, effective treatment for posterior-canal BPPV. The Cochrane review pooled 745 patients across 11 mostly-small randomised trials; both the odds of complete symptom resolution and the odds of converting a positive Dix-Hallpike test to negative strongly favoured the Epley manoeuvre over sham or control. This is the landmark receipt for "reposition it." (Hilton MP & Pinder DK. "The Epley (canalith repositioning) manoeuvre for benign paroxysmal positional vertigo." Cochrane Database Syst Rev 2014, CD003162.pub3. Strong Evidence — a Cochrane systematic review of RCTs. Notably, no commercial sponsor stands behind the manoeuvre: no company profits from a free five-minute bedside procedure, which plausibly contributes to its under-use versus marketed drugs — here the money runs AGAINST the cheap, effective option.)

2. The repositioning geometry is the active ingredient — add-ons and gadgets do nothing. A separate Cochrane review found no benefit from mastoid oscillation applied during the Epley manoeuvre, and no clinically important benefit from post-manoeuvre postural restrictions (wearing a collar, sleeping upright). The manoeuvre itself, done correctly, is what works. (Hunt WT, Zimmermann EF, Hilton MP. "Modifications of the Epley (canalith repositioning) manoeuvre for posterior canal benign paroxysmal positional vertigo." Cochrane Database Syst Rev 2012, CD008675. Strong Evidence — Cochrane review; supports the minimum-effective-dose framing that the cure is the geometry, not the accessories.)

The default is backwards: the drug is over-used, the cure under-used (Moderate, observational).

3. The curative manoeuvre is drastically under-delivered exactly where BPPV is most common. In a primary-care cohort of 458 BPPV patients, only 11.1% received the Epley manoeuvre, while 57.4% were given a vestibular-suppressant medication and 54% never received a diagnostic positional (Dix-Hallpike) exam at all. The ineffective drug is the default; the curative manoeuvre is the exception. (Guideline Adherence to BPPV Treatment and Management in Primary Care, PMC10782547. Moderate Evidence — an observational cohort documenting the real-world practice gap, not a trial of efficacy. Documents the reversal, not the reason.)

The guideline agrees: don't reach for the drug (Strong).

4. National specialty guidance recommends clinicians should NOT routinely treat BPPV with vestibular suppressants. The 2017 American Academy of Otolaryngology–Head and Neck Surgery clinical practice guideline (update) states that clinicians should not routinely treat BPPV with vestibular-suppressant medications (antihistamines and/or benzodiazepines); a stated objective of the guideline is to reduce inappropriate vestibular-suppressant use, in favour of repositioning, observation with follow-up, or vestibular rehabilitation. (Bhattacharyya N, et al. "Clinical Practice Guideline: Benign Paroxysmal Positional Vertigo (Update)." Otolaryngol Head Neck Surg 2017;156(3_suppl):S1–S47. Strong Evidence — a national specialty-society guideline with an explicit recommendation-against. The direction of this recommendation runs against the pharma-favoured option, which strengthens rather than weakens its credibility.)

The marketed "vertigo drug" is weak evidence and not a BPPV cure (Emerging/low-grade).

5. Betahistine — the classic branded "vertigo drug" — shows at best a small, non-specific effect and is not a BPPV cure. Cochrane pooled 606 participants across 11 studies: betahistine reduced vertigo symptoms versus placebo with a risk ratio of 1.30 (95% CI 1.05–1.60), but the GRADE quality of evidence was LOW, with high or unclear risk of bias and heterogeneity across the trials. It treats a symptom, not the crystal displacement. (Murdin L, Hussain K, Schilder AGM. "Betahistine for symptoms of vertigo." Cochrane Database Syst Rev 2016, CD010696.pub2. Emerging Evidence — low-GRADE, for a modest, non-BPPV-specific effect. The COI tell: the large "positive" VIRTUOSO study for betahistine was industry-funded, open-label and observational with no placebo control, while the best-quality blinded-RCT evidence is the weakest — a classic industry-optimism-versus-trial-rigour gap.)

The red flag: a central mimic is real, dangerous, and not a home test (Strong for the exam, in expert hands).

6. Sudden vertigo can be a stroke, and the bedside signs that separate it are more sensitive than early MRI — but only in trained hands. In acute vestibular syndrome, the HINTS three-step oculomotor exam (Head-Impulse, Nystagmus, Test-of-Skew) identified stroke with approximately 100% sensitivity in the derivation cohort — more sensitive than early diffusion-weighted MRI, which missed roughly 12% of posterior-circulation strokes in the first 24–48 hours. The crucial caveat: this near-perfect sensitivity was achieved by trained neuro-otologists; it drops with less-expert examiners and does not transfer to self-assessment. (Kattah JC, Talkad AV, Wang DZ, Hsieh YH, Newman-Toker DE. "HINTS to diagnose stroke in the acute vestibular syndrome: three-step bedside oculomotor examination more sensitive than early MRI diffusion-weighted imaging." Stroke 2009;40(11):3504–3510. Strong Evidence for the exam in expert hands — a landmark prospective diagnostic-accuracy study; academic/NIH-adjacent, no commercial interest. Read the caveat as load-bearing: "a reassuring exam rules out stroke" is true for the neuro-otologist, not for a worried person at home.)

Mechanism

This entry owns enough mechanism to make "reposition it, don't medicate it" and the stroke boundary intelligible — not the full neuro-anatomy.

Why BPPV is mechanical, and why that means a manoeuvre and not a molecule. The utricle, a chamber in the inner ear, is normally studded with otoconia — microscopic calcium-carbonate crystals that give it its sense of gravity and linear motion. In BPPV, some of these crystals break loose and drift into one of the semicircular canals (most often the posterior canal). Now, every time the head changes position, gravity drags the loose crystals through the canal fluid, deflecting the sensor and firing a false, violent signal of spinning — for a few seconds, until they settle. That is why the vertigo is positional (triggered by rolling over, lying down, looking up) and brief and repeatable. Nothing swallowed can push a crystal back up a canal. The Epley manoeuvre can: a sequence of timed head-and-body positions uses gravity to walk the crystals around the canal loop and drop them back into the utricle, where they no longer disturb rotation sensing. The fix is geometric, which is exactly why drugs miss it and add-on gadgets are superfluous.

Why vestibular suppressants can prolong the problem, not just fail to fix it. Drugs like meclizine and betahistine dampen the brain's response to the vestibular mismatch — they mute the sensation of spinning. But muting the alarm does two unhelpful things: it removes the trigger to seek the definitive repositioning fix, and (mechanistically, per guideline logic) it may blunt the central compensation and the positional testing needed to confirm and treat BPPV, delaying resolution. So the drug can turn a condition curable in one visit into weeks of managed symptoms. (Note the honesty limit in RISKS: "delays the cure and sedates" is well-supported; "proven by RCT to lengthen time-to-resolution" is not.)

Why true vertigo is not the same problem as feeling faint. Spinning vertigo — the room moving, a rotatory illusion — is a vestibular signal. Lightheadedness or presyncope ("I'm about to pass out") is usually a blood-flow or blood-pressure problem; disequilibrium ("I'm unsteady on my feet") is often sensory or musculoskeletal. The otolith-repositioning story applies only to the first. Mislabelling a near-faint as "vertigo crystals" sends you down the wrong track entirely.

Why the central mimic exists and why it hides. The vestibular nerve and inner ear are the peripheral apparatus; the brainstem and cerebellum process their signals. A posterior-circulation stroke damages that central processing and can produce vertigo indistinguishable, at first glance, from a peripheral spin. The tells are neurological — the pattern of the eye movements (direction-changing or vertical/torsional nystagmus, a normal head-impulse test, skew deviation) and accompanying signs (new severe headache, double vision, slurred speech, facial or limb weakness, inability to stand or walk). These are what the HINTS exam reads, and why sudden vertigo with any such sign is treated as a stroke until proven otherwise.

Risks And Contraindications

• THE STROKE MISS — the load-bearing safety item. Not all sudden vertigo is benign. Sudden, severe, continuous vertigo accompanied by ANY neurological sign — new or severe headache, double vision (diplopia), slurred speech (dysarthria), facial or limb weakness or numbness, inability to stand or walk, or direction-changing / vertical / torsional nystagmus — can be a posterior-circulation stroke and is a same-day emergency. Two hard sub-points: early MRI can be falsely negative in the first 24–48 hours, so a normal early scan does not clear it; and the HINTS exam that reliably distinguishes central from peripheral is expert-performed, not a home test — its near-perfect sensitivity belongs to trained neuro-otologists, not to self-assessment. Never let "it's probably just my ears" be a self-diagnosis that talks you out of emergency care.
• True vertigo is not lightheadedness. The mechanical-crystal story and the Epley manoeuvre apply ONLY to genuine positional spinning vertigo. Presyncope ("about to faint"), disequilibrium ("unsteady"), and chronic dizziness are different problems with different (sometimes cardiovascular) causes — do not force them into the BPPV frame; route them to fatigue_cross_pillar_diagnostic / cardiovascular_health_management.
• "Suppressants can prolong it" — state it honestly. That vestibular suppressants cause prolonged BPPV is mechanistically reasonable and consistent with guideline logic (they mask symptoms and delay definitive repositioning), and they carry known harms — sedation, worsened balance, and increased fall risk, especially in the elderly. But that they measurably lengthen time-to-resolution is NOT proven by RCT. Frame it as delay-of-cure plus known sedation/fall harm, not as a hard causal claim.
• Confirm BPPV before treating it as BPPV. The diagnosis rests on a positive Dix-Hallpike (characteristic latency then torsional up-beating nystagmus). Horizontal- and anterior-canal variants exist and need different manoeuvres; vertigo with hearing loss or ear fullness (possible Ménière's) or with days of continuous spinning after a viral illness (possible vestibular neuritis) is not posterior-canal BPPV and needs clinician assessment.
• Don't over-sell self-repositioning. The single most dangerous inversion of this entry's message is "just reposition it yourself." Self-Epley is reasonable for a confirmed, canal-identified, red-flag-negative recurrence — not as a substitute for first-episode diagnosis or for clearing the stroke mimic.
• Avoid the opposite over-correction. "Repositioning is a gimmick" is also wrong: the Cochrane evidence for the Epley manoeuvre is Strong. The honest message is "mechanical fault, mechanical fix, but rule out the dangerous mimic first," not a dismissal of the manoeuvre.

Controversy

Nature: a condition with a proven, free, minutes-long cure that is systematically under-delivered in favour of a drug that does not address the mechanism — wrapped around a genuinely dangerous exception (the central mimic). Error is possible at both poles: under-treating (defaulting to suppressants and supplements instead of repositioning) and over-reassuring (self-diagnosing benign vertigo and missing a stroke).

Position A — "It's mechanical, so reposition it, not medicate it." The curative-manoeuvre take.
• Best evidence: Cochrane rates the Epley manoeuvre safe and effective for posterior-canal BPPV (745 patients, 11 RCTs); the geometry is the active ingredient (add-ons add nothing); national guidance recommends AGAINST routine vestibular suppressants; and the curative manoeuvre is under-delivered (≈11% in primary care) while the ineffective drug is the default.
• Where it goes wrong if overstated: it slides into "do the Epley off a video and skip the doctor," which discards the diagnosis step and the stroke rule-out.

Position B — "Not all sudden vertigo is benign." The red-flag take.
• Best evidence: a posterior-circulation stroke can mimic peripheral vertigo; the HINTS exam is more sensitive than early MRI (which misses roughly 12% of these strokes early); sudden vertigo with neurological signs is an emergency.
• Where it goes wrong if overstated: it can tip into "all dizziness needs the ER / a scan," which medicalises the commonest, most fixable cause and leaves people on ineffective drugs.

The funding/bias dimension — cui bono, both ways. Toward the drug: the money is on the ineffective-for-BPPV options. Betahistine (Serc/Betaserc, historically Abbott) and meclizine/antihistamines are branded, prescribed and promoted, and betahistine's flagship "positive" evidence (the VIRTUOSO study) is industry-funded, open-label and uncontrolled — while the best blinded-RCT (Cochrane) evidence is only low-grade. "Vertigo supplements" ride the same demand with no BPPV mechanism at all. The curative manoeuvre has no sponsor because no one profits from a free bedside procedure, which is a plausible part of why it is under-taught and under-delivered. Toward over-reassurance: cui bono the other way is subtle but real — the entry's own "go get repositioned" message could be over-sold into DIY self-treatment that skips the stroke rule-out, so the honest read must protect the red flag as hard as it protects the anti-drug point.

Realised Position: It's mechanical — reposition it. For true positional vertigo confirmed as BPPV, the Epley manoeuvre is the evidence-based first move, not a prescription; drugs and supplements are not a cure and can prolong the problem and sedate. But vertigo is not a self-diagnosis game: spinning vertigo is not the same as feeling faint, and sudden severe vertigo with any neurological sign (new headache, double vision, slurred speech, limb weakness, inability to walk, direction-changing or vertical nystagmus) is a same-day emergency to exclude stroke — HINTS is an expert exam, not a home test, and early MRI can miss it. Confirm it, clear the mimic, then reposition it.

Cross-Pillar Connections

BPPV/vertigo is an ear-mechanical problem with a neurological red flag, so its connections span the ear-symptom, cardiovascular/neuro, and diagnostic lines.
• Conditions (cardiovascular_health_management): owns actual stroke/cardiovascular management and blood-pressure causes of lightheadedness; this entry holds only that a central (stroke) mimic exists and is a same-day emergency, and defers management there.
• Conditions (tinnitus_evidence_and_management): the neighbouring inner-ear symptom; relevant when vertigo comes with ringing or ear fullness (which can point toward Ménière's rather than BPPV) — route the ear-noise question there.
• Cross-pillar (fatigue_cross_pillar_diagnostic): the broader "why am I dizzy / off / exhausted" work-up for non-spinning dizziness, presyncope and disequilibrium that are NOT BPPV; this entry hands those off rather than forcing them into the crystal frame.
• Foundations (publication_bias_and_evidence_distortion): the mechanism behind the betahistine pattern — an uncontrolled industry study looking stronger than the blinded RCTs — and behind selective citation of drug benefit.
• Foundations (minimum_effective_dose): the manoeuvre-not-the-gadget point — the repositioning geometry is the active ingredient, and mastoid oscillators and postural restrictions add nothing; the minimum effective intervention is the correctly performed manoeuvre.

What would change our mind

Falsifiability: explicit upgrade/downgrade criteria from source

• We'd revise the anti-drug stance if a large, low-risk-of-bias, placebo-controlled RCT showed a vestibular suppressant or supplement actually RESOLVES BPPV — converting a positive Dix-Hallpike to negative as well as or better than the Epley manoeuvre. None exists; current drug evidence is symptom-masking at best, and no supplement has a repositioning mechanism.
• We'd loosen the "keep the red flag clinician-gated" line if high-quality evidence showed that self-administered or untrained-examiner HINTS retains near-100% stroke sensitivity. The current data point the other way — sensitivity is examiner-dependent — which reinforces keeping the rule-out with clinicians, not home triage.
• We'd upgrade "suppressants can prolong it" from mechanistic-plus-guideline-logic to a proven claim if a definitive RCT quantified that early suppressant use measurably lengthens time-to-resolution. Right now the defensible claim is delay-of-cure plus known sedation/fall harm, not a hard causal effect on duration.
• What would sharpen, not overturn, the framing: head-to-head data showing self-Epley or the Semont manoeuvre matching clinician Epley would strengthen "it's mechanical, reposition it," not weaken it — the lever is still the geometry, not a drug.

Industry bias note

Structural incentives the evidence base may reflect

Cui bono runs sharply asymmetric here, and the asymmetry is the story.
• The curative option has no sponsor — and is under-marketed because of it. The Epley manoeuvre is a free, minutes-long bedside procedure. No company profits from it, so nothing funds its promotion, and it stays under-taught and under-delivered (≈11% of primary-care BPPV patients) despite Strong Cochrane support. When the cheap, effective option is the neglected one, absence-of-a-seller is doing the neglecting.
• The ineffective-for-BPPV options are the ones with sponsors. Betahistine (Serc/Betaserc) and meclizine/antihistamines are branded, prescribed and promoted. Betahistine's flagship "positive" evidence — the VIRTUOSO study — is industry-funded, open-label and uncontrolled, while the best blinded-RCT (Cochrane) evidence for it is only low-grade. That inversion (impressive-looking uncontrolled data, weak controlled data) is the classic industry-optimism-versus-trial-rigour tell — see publication_bias_and_evidence_distortion.
• "Vertigo supplements" ride the demand with no mechanism. Ginkgo and ear-health vitamin blends are sold into the same worry with no otolith-repositioning rationale at all.
• The reverse cui-bono check — protect the red flag. The honest corrective is not free of its own risk: an "anti-drug, go-get-repositioned" message can be over-sold into DIY self-treatment that skips the stroke rule-out. So the bias analysis cuts both ways — the entry must guard the emergency boundary as hard as it debunks the drug default, because the demand for a simple self-fix is itself a pull toward a dangerous miss.

Net pattern: the money pushes toward the symptom-masking drug and away from the free cure, and the strongest counter-evidence (Cochrane, national guideline) is conflict-clean — but the counter-message carries its own over-correction risk that the entry names explicitly.

Vertigo: The Most Common Kind Is Cured in Minutes, Not With Pills